Previous close | 44.11 |
Open | 44.30 |
Bid | 43.94 x 2900 |
Ask | 44.07 x 1400 |
Day's range | 43.73 - 44.30 |
52-week range | 43.33 - 67.16 |
Volume | |
Avg. volume | 15,389,326 |
Market cap | 89.253B |
Beta (5Y monthly) | 0.44 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.40 (5.45%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | N/A |
PRINCETON, N.J., May 16, 2024--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J., May 16, 2024--Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J., May 10, 2024--Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial